Charles Schwab Investment Management Inc Arcus Biosciences, Inc. Transaction History
Charles Schwab Investment Management Inc
- $601 Billion
- Q3 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 871,150 shares of RCUS stock, worth $17.5 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
871,150
Previous 776,742
12.15%
Holding current value
$17.5 Million
Previous $6.32 Million
87.39%
% of portfolio
0.0%
Previous 0.0%
Shares
31 transactions
Others Institutions Holding RCUS
# of Institutions
212Shares Held
67.7MCall Options Held
3.3MPut Options Held
146K-
Black Rock Inc. New York, NY9.76MShares$196 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.63MShares$133 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.33MShares$87 Million0.12% of portfolio
-
Woodline Partners LP San Francisco, CA3.77MShares$75.7 Million0.26% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.69MShares$74 Million1.51% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.45B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...